The class III variant of the epidermal growth factor receptor (EGFRvIII): Characterization and utilization as an immunotherapeutic target

Journal of NeuroVirology

Volumn 4, Issue 2, 1998, Pages 148-158

  Wikstrand, G J ^a   Reist, C J ^a   Archer, G E ^a   Zalutsky, M R ^a   Bigner, D D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glioblastoma; Growth factor receptors; Immunotherapy; Internalization; Tumor specific antigen

Indexed keywords

CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; RECEPTOR ANTIBODY; TUMOR ANTIGEN;

AUTOPHOSPHORYLATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DIMERIZATION; DRUG TARGETING; GLIOMA; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN VARIANT; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

EID: 7144261725     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.3109/13550289809114515     Document Type: Review

References (63)

1. Agosti RM, Leuthold M, Gullick WJ, Yasargil MG, Wiestler OD. (1992). Expression of the epidermal growth factor receptor in astrocytic tumours is specifically associated with glioblastoma multiforme. Virchows Archiv A Pathol Anat 420: 321-325.
2. Archer GE, Fuchs HE, Sampson JH, Wikstrand CJ, Lorimer IAJ, Pastan I, Bigner DD. (1997). In vivo efficacy of a single chain immunotoxin (MR1) targeting a deletion mutant of EGFR. J Neuro-oncology 35: Supplement 1, S6 (abstr.).
3. Arteaga CL, Hurd SD, Dugger TC, Winnier AR. Robertson JB. (1994). Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor α-Pseudomonas exotoxin 40 fusion protein. Cancer Res, 54: 4703-4709.
4. Ashley DM, Sampson JH, Archer GE, Batra SK, Bigner DD, Hale LP. (1997) A genetically modified allogeneic cellular vaccine generates MHC class-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumor challenge. J Neuroimmunology 78: 34-46.
5. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman SH, Bigner DD. (1995). Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth and Diff 6: 1251-1259.
6. Batra SK, Rasheed BKA, Bigner SH, Bigner DD. (1994). Oncogenes and anti-oncogenes in human central nervous system tumors. Lab Invest 71: 621-637.
7. Beguinot L, Lyall RM, Willingham MC, Pastan I. (1984). Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes. Proc Natl Acad Sci USA 81: 2384-2388.
8. Bigner SH, Batra SK, Rasheed BKA. (1998). Mechanisms of altered growth control. Cytogenetics, oncogenes and suppressor genes. In: Russell and Rubinstein's Pathology of the Nervous System. Sixth Edition. Bigner DD, Mclendon RE, Brunder JM (eds). Arnold Publishing: London, in press.
9. Bigner SH, Friedman HS, Vogelstein B, Oakes WJ, Bigner DD. (1990a). Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res 50: 2347-2350.
10. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Freidman HS, Bigner DD. (1990b). Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50: 8017-8022.
11. Bigner SH, Wong AJ, Mark J, Muhlbaier LH, Kinzler KW, Vogelstein B, Bigner DD. (1987). Relationship between gene amplification and chromosomal deviations in malignant human gliomas. Cancer Genet Cytogenet 29: 165-170.
12. Cadena DL, Chan C, Gill GN. (1994) The intracellular tyrosine kinase domain of the epidermal growth factor receptor undergoes a conformational change upon autophosphorylation. J Biol Chem 269: 260-265.
13. Carter TH, Kung HJ. (1994). Tissue-specific transformation by oncogeneic mutants of epidermal growth factor receptor. Crit Rev Oncogen 5: 389-428.
14. Chen WS, Lazar CS, Lund KA, Welsh JB, Change CP, Walton GM, Der CJ, Wiley HS, Gill GN, Rosenfeld MG. (1989). Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation. Cell 59: 33-43.
15. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD. (1997). Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 324: 855-861.
16. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. (1991). Genes for epidermal growth factor receptor, transforming growth factor alpha and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164-2172.
17. Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Lui L, Collins VP, James CD. (1994). Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastoma with EGFR gene amplification. Oncogene 9: 2313-2330.
18. Ekstrand AJ, Sugawa N, James CD, Collins VP. (1992). Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 89: 4309-4313.
19. Fuller GN, Burger PC, Schold SC, Preisinger A, Wong AJ, Bigner DD, Vogelstein B, Bigner SH. (1990). Gene amplification in human gliomas. J Neuropathol Exp Neurol 49: 320. [abstr].
20. Garcia de Palazzo IE, Adams GP, Sundareshan P, Wong AJ, Testa JR, Bigner DD, Weiner LM. (1993). Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53: 3217-3220.
21. Gullick WJ, Downward J, Parker PJ, Whittle N, Kris R, Sclessinger J, Ulrich A, Waterfield MD. (1985). The structure and function of the epidermal growth factor receptor studied by using anti-synthetic peptide antibodies. Proc Royal Soc London (Biol) 2256: 127-134.
22. Gullick WJ, Marsden JJ, Whittle N, Ward B, Bobrow L, Waterfield MD. (1986). Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res 45: 285-292.
23. Herbst JJ, Opresko LK, Walsh BJ, Lauffenburger DA, Wiley HS. (1994). Regulation of postendocytic trafficking of the epidermal growth factor receptor through endosomal retention. J Biol Chem 269: 12865-12873.
24. Hills D, Rowlinson-Busza G, Gullick WJ. (1995) Specific targeting of a mutant, activated EGF receptor found in glioblastoma using a monoclonal antibody. Int J Cancer 63: 537-543.
25. Hollstein MC, Smits AM, Galiana C, Yamasaki h, Bos JL, Mandard A, Partensky C, Montesano R. (1988). Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers. Cancer Res 48: 5119-5123.
26. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965.
27. Huang JJS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji SD, Huang CM, Gill GN, Wiley HS, Cavanee WK. (1997). The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272: 2927-2935.
28. Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH, Bigner DD, Bigner SH. (1988). Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48: 2231-2238.
29. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, Friedman HS, Kwatra MM, Bigner SH, Bigner DD. (1990). Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 87: 4207-4211.
30. Kinzler KW, Bigner SH, Bigner DD, Trent JM, Law ML, O'Brien SJ, Wong AJ, Vogelstein B. (1987). Identification of an amplified highly expressed gene in a human glioma. Science 236: 70-73.
31. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax B, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J. (1985). Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147.
32. Lorimer IAJ, Deppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I. (1996). Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 93: 14815-14820.
33. Lorimer IAJ, Wikstrand CJ, Batra SK, Bigner DD, Pastan I. (1995). Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin Cancer Res 1: 859-864.
34. Merlino GT, Xu Y, Richer N, Clark AJL, Ishii S, Banks-Schlegel S, Pastan I. (1985). Elevated epidermal growth factor receptor gene copy number and expression in a squamous carcinoma cell line. J Clin Invest 75: 1977-1979.
35. Montgomery RB, Moscatello DK, Wong AJ, Cooper JA, Stahl WL. (1995). Differential modulation of mitogenactivated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J Biol Chem 270: 30562-30566.
36. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ. (1995). Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55: 5536-5539.
37. Moscatello DK, Montgomery RV, Sundaresham P, McDanel H, Wong MY, Wong AJ. (1996). Transformation and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13: 85-96.
38. Moscatello DK, Ramirez G, Wong AJ. (1997). A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 57: 1419-1424.
39. Nishikawa R, Ji SC, Harmon RC, Lazar CS, Gill GN, Cavenee WK. Huang HJS. (1994). A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91: 7727-7731.
40. Owens OJ, Steward C, Leake RE, McNicol AM. (1992). A comparison of biochemical and immunohistochemical assessment of EGFR expression in ovarian cancer. Anticancer Res 12: 1455-1458.
41. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Huang HJS. (1996). Enhanced tumorigenic behaviour of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 271: 25639-25645.
42. Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR. (1995). Tumor-specific antiepidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 55: 4375-4382.
43. Reist CJ, Archer GE, Wikstrand CJ, Bigner DD, Zalutsky MR. (1997a). Improved targeting of an anti-EGFRvIII monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res 57: 1510-1515.
44. Reist CJ, Batra SK, Pegram CN, Bigner DD, Zalutsky MR. (1997b). In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: Comparison with its murine parent. Nucl Med Biol 24: 639-647.
45. Reist CJ, Garg PK, Alston KL, Bigner DD, Zalutsky MR. (1996). Radioiodination of internalizing monoclonal antibodies using N-Succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res 56: 4970-4977.
46. Restifo PR, Wunderlich JR. (1995). Biology of cellular immune responses. In: Biologic therapy of cancer. DeVita VT, Hellman S, Rosenberg IAS (eds). Lippicott: Philadelphia, pp. 3-39.
47. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E. (1993). Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53: 2379-2385.
48. Schlegel J, Merdes A, Stumm G, Albert Fk, Forsting M, Hynes N, Kiessling M. (1994a). Amplification of the epidermal growth factor receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 56: 72-77.
49. Schlegel J, Stumm G, Brandie K, Merdes A, Mechtersheimer G, Hynes NE, Kiessling M. (1994b). Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J Neuro-Oncol 22: 201-207.
50. Schwechheimer K, Huand S, Cavenee WK. (1995). EGFR gene amplification-rearrangement in human glioblastomas. Int J Cancer 62: 145-148.
51. Suárez-Quian CA, Byers SW. (1993). The distribution of epidermal growth factor receptor as a function of cell density, cell-cell adhesion and calcium in human (A-431) cells. Tissue and Cell 25: 1-17.
52. Sugawa W, Ekstrand AJ, James CD, Collins VP. (1990). Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87: 8602-8606.
53. Torp SH, Helseth E, Dalen A, Unsgaard G. (1991). Epidermal growth factor receptor expression in human gliomas. Cancer Immunol Immunother 33: 61-64.
54. Wikstrand CJ, Fung KM, Trojanowski JQ, McLendon RE, Bigner DD. (1998). Antibodies and molecular immunology. Immunohistochemistry and antigens of diagnostic signficance. In: Russel and Rubinstein's Pathology of the Nervous System. Sixth Edition. Bigner DD, McLendon RE and Bruner JM (eds). Arnold Publishing: London, in press.
55. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek ST, Wong AJ, Zalutsky MR, Bigner DD. (1995). Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55: 3140-3148.
56. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. (1997). Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57: 4130-4140.
57. Wikstrand CJ, Stanley SD, Humphrey PA, Pegram CN, Archer GE, Kurpad SN, Shibuya M, Bigner DD. (1993). Investigation of a synthetic peptide as immunogen for a variant epidernal growth factor receptor associated with gliomas. J Neuroimmunol 46: 165-174.
58. Willingham MC, Pastan IH, Sahagian GG, Jourdian GW, Neufeld EF. (1981). Morphologic study of the internalization of a lysosomal enzyme by the mannose 6-phosphate receptor in cultures Chinese hamster ovary cells. Proc Natl Acad Sci USA 78: 6967-6971.
59. Willingham MC, Pastan IH. (1982). Transit of epidermal growth factor through coated pits of the golgi system. J Cell Biol 94: 207-212.
60. Woltjer RL, Lukas TJ, Staros JV. (1992). Direct identification of residues of the epidermal growth factor receptor in close proximity to the amino terminus of bound epidermal growth factor. Proc Natl Acad Sci USA 89: 7801-7805.
61. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. (1987). Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899-6903.
62. Wong AJ, Rupper JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DD, Vogelstein B. (1992). Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89: 2965-2969.
63. Yamazaki H, Ohba Y, Tamaoki N, Shibuya M. (1990). A deletion mutation within the ligand binding domain is reponsible for activation of epidermal growth factor receptor gene in human brain tumors. Jap J Cancer Res 81: 773-779.